Danaher Gains On $9.6 Billion Aldevron Buy For Genomic Play

© Reuters.

By Dhirendra Tripathi

Investing.com – Danaher (NYSE:) shares were up more than 4% Thursday as the company announced it will buy privately-held Aldevron for $9.6 billion in cash.

Aldevron manufactures high-quality plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications.

Danaher President and Chief Executive Officer Rainer M. Blair said the acquisition will expand the company’s capabilities in genomic medicines and help it bring more life-saving therapies and vaccines to market faster.

Aldevron will operate as a standalone operating company and brand within Danaher’s life sciences segment.

Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance of commercial paper.


Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

See also  Air France-KLM's future in doubt without cost cuts - Dutch minister



Please enter your comment!
Please enter your name here